Anticoagulation prophylaxis in COVID-19

Thursday | June 17, 2021 | 11:00am - 12:00pm ET

Join the Anticoagulation Forum and manuscript authors as we discuss the methods, findings, and implications of recent randomized, controlled studies evaluating VTE prophylaxis strategies on clinical outcomes among moderate and severe COVID-19 hospitalized patients.

**Presenters**
- Behnood Bikdeli, MD, MS
- Stacy Ellsworth, RN, MSN, CCRC
- Scott Kaatz, DO, MSc
- Patrick Lawler, MD, MPH

**Moderator**
- Tracy Minichiello, MD

Links to Articles:
- Therapeutic Anticoagulation in Critically Ill Patients with Covid-19
- Therapeutic Anticoagulation in Non-Critically Ill Patients with Covid-19
- ACTION Trial
- INSPIRATION Trial

**Combination Aspirin & DOAC Therapy Increases Bleeding Risk**

Wednesday | July 21, 2021 | 12:00 - 1:00pm ET

From the multi-center MAQI consortium, the authors explored the increased risk of bleeding when patients who were prescribed DOAC medications also were taking aspirin therapy.

Learn more about how the data was collected, how the analyses were conducted, and what steps are being taken to reduce unnecessary aspirin use in order to try and reduce bleeding complications.

**Authors**
- Jordan Schaefer, MD
- Geoffrey Barnes, MD, MSc
Previously Recorded Webinars

**New Clinical Guide for Managing Direct Oral Anticoagulants (DOACs)**
*Recorded on May 5, 2021*

The Anticoagulation Forum is very pleased to announce the publication of our new “DOAC Playbook”. This comprehensive guide provides practical information for clinicians who prescribe, monitor, and manage patients on DOACs. Watch the recorded webinar hosted by four of the DOAC Playbook authors highlighting this new AC Forum resource through patient case examples.

![Watch](play)

**View the DOAC Playbook here**

**Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation**
*Recorded on May 25, 2021*

Direct oral anticoagulants (DOACs) are increasingly used in place of warfarin, but evidence about their effectiveness and safety in patients with valvular atrial fibrillation (AF) remains limited.

In this comparative effectiveness study using practice-based claims data, patients with valvular AF who were new users of DOACs had lower risks for ischemic stroke or systemic embolism and major bleeding than new users of warfarin. This data may be used to guide risk–benefit discussions regarding anticoagulant choices for patients with valvular AF.

![Watch](play)

To Claim Enduring Credit, just click on claim cme!
We are thrilled to announce that our National Conference will be held in-person on **October 28-30, 2021 in San Francisco, CA**, as well as broadcast virtually.

Our conference features over 30 nationally recognized anticoagulation experts, who will each be presenting live, in-person! Visit our conference website for the full program agenda.

**Register by July 1st for Early Bird Rates**

---

**Reminder – Deadline for Scholarships & Abstract Research Award!**

**June 10th, 2021**

The AC Forum is pleased to offer scholarships to our National Conference support the ongoing education of clinicians from underrepresented racial and ethnic groups.

All awards include:
- Complementary registration to National Conference (minimum $345 value)
- Travel stipend of $1500 to cover transportation and lodging at the conference hotel

**Eligibility:**
Applicants must be clinicians from underrepresented racial/ethnic groups OR (for abstract research award) a clinician conducting research on racial health disparities.

*Note: Abstracts do not need to be finalized in order to apply for the research award. Application materials include a title, description, and statement on how your research will impact the field of anticoagulation.*

**Apply Now**

---

**Pharmacy and Medically Underserved Areas Enhancement Act**

Legislation for the *Pharmacy and Medically Underserved Areas Enhancement Act* was recently introduced in both the US House of Representatives (H.R. 2759) and the Senate (S. 1362). This bill will recognize pharmacists as health care providers for Medicare patients, granting pharmacists “provider status” and mandating pharmacists are fairly compensated for their patient care services.

As this legislation has the potential to expand patient access to clinical pharmacy services and improve the sustainability of anticoagulation-related services in underserved areas, we encourage the multi-disciplinary membership of the Anticoagulation Forum to support its passage.

The American Pharmacists Association has created a pre-written, editable advocacy alert that you may use to ask your U.S. Representative and Senators to co-sponsor the bill (H.R. 2759/S. 1362) or thank them if they have already signed on to the legislation. The form will automatically populate with the correct “please support” or “thank you” text based on your address.

**Complete the Form**
Congratulations to our 2020-21 Ansell Fellows!
Leili Behrooz, MD, MPH - Boston Medical Center
Ahmed Pasha, MD - Mayo Clinic
Tom Alsaigh, MD - Stanford University
Kirolus Sourial, MD - University Hospitals Cleveland Medical Center
Henry Han, MD - University of Michigan
Anna Griffith, MD - University of North Carolina School of Medicine

The Anticoagulation Forum Ansell Fellowship program supports the advanced training of physicians in anticoagulation-related fields, with the goal of increasing the number of expert clinicians equipped to provide evidence-based management to patients at risk for thrombosis.

In addition to their on-site education, Fellows also participated in a bi-weekly virtual seminar series focused on key subject matter topics within the vascular medicine core curriculum, as well as those related to Career Development and Research Development.

Over the past year, our Fellows attended seminars on:
- Developing Research in Vascular Medicine
- Complex Cases in Anticoagulation and VTE
- Fibromuscular Dysplasia & Zebra Vascular Disease
- The Vascular Biology of Atherosclerosis
- Nuts and Bolts: Work-Up & Management of Unexplained Arterial Thromboembolism
- ABVM & RPVI Exam Overview
- And more!

Congratulations once again to this new generation of providers!

Learn More About the Ansell Fellowship Program

As the field of anticoagulation continues to quickly evolve and become more nuanced, Rapid Resources aim to provide succinct one-page to two-page summaries to help providers stay informed.

This library of compact info sheets is housed in the ACE Rapid Resources section located on the left of our ACE Resource Center. New materials are added regularly!

Don't miss the over 500 resources in our Library.

Literature Resource Updates!
Here is the breakdown of new articles:
> May 3, 2021 update, 88 new articles, including 15 related to COVID-19
> May 24, 2021 update, 83 new articles, including 14 related to COVID-19

Special thanks to Dr. Bishoy Ragheb who updates our literature search by topic!

Pharmacy Practice News

Now available: New Guidance for Managing DOAC-Related Bleeding by Karen Blum

Read Article

Supporting our Partners

5 MINUTE ON-DEMAND UPDATES:
Anticoagulation Management of Patients With COVID-19

Presented by Scott Kaatz, DO, MSc, FACP, SFHM

Available for viewing June 2021

Scott Kaatz, DO, MSc, FACP, SFHM, shares the latest guidance for therapeutic anticoagulation in hospitalized patients with COVID-19, based on the latest data and ongoing trials in two 5-minute on-demand updates, available on video or podcast beginning June 7, 2021

Pre-register to receive notification when the On-Demand program is available

Pre-register Now

Updates will be available for download June 7 – July 7, 2021

These On-Demand programs, Anticoagulation Management of Patients With COVID-19, are brought to you by Bedford Scientific through an Independent Medical Education Grant from Pfizer Inc and are not affiliated with AC Forum.

Researchers at the University of Utah Department of
Pharmacotherapy and Biomedical Informatics would like to invite you to review a provider-patient share decision making tool call DDInteract. DDInteract predicts the gastrointestinal bleeding risk for patients on warfarin and NSAIDs considering different attributes of the patients.